21 March 2022 ORYZON announces FDA approval of IND for FRIDA, a Phase Ib trial with iadademstat in R/R AML FLT3mut+ patients
2 March 2022 Epigenetics Symposium – From Genes to Chromatin to Therapeutics Philadelphia PA United States
11 January 2022 ORYZON announces new Senior VP of Clinical Development and Global Medical Affairs, continuing its expansion of US corporate activities
4 January 2022 ORYZON announces approval for Serbian arm of PORTICO, vafidemstat’s Phase IIb trial in Borderline Personality Disorder